|
|
|
|
Danfors T, Ribom D, Ghaderi Berntsson S, Smits A. Epileptic seizures and survival during early disease in grade 2
gliomas. Eur J Neurol 2009; 16:, 823-31.
Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L. Oligodendrocyte progenitor cells can act as cell of origin for
experimental glioma. Oncogene 2009; 28: 2266-2275.
Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to EORTCs prognostic factors in grade 2 gliomas.
Eur J Nucl Med 2008; 1: 65-71.
Hagerstrand D, Smits A, Eriksson A, Sigurdardottir S, Olofsson T, Nistér M, Kalimo H, Östman A. Gene expression
analyses of grade II gliomas and identification of rPTP beta/zeta as a candidate oligodendroglioma marker. Neuro-oncol
2008; 1:, 2-9.
Qu M, Olofsson T, Sigurdardottir S, Kalimo H, Nistér M, Smits A, Ren Z-P. Genetically distinct astrocytic and
oligodendroglial components in oligoastrocytoma. Acta Neuropathol 2007; 113: 129-136.
Ren Z-P, Olofsson T, Qu M, Hesselager G, Soussi T, Kalimo H, Smits A, Nistér M. Molecular genetic analysis of p53
intratumoral heterogeneity in human astrocytic tumors. J Neuropathol Exp Neurol 2007; 66: 944-954.
A. Granat, G. Ahlström, A. Smits. Ett nytt integrerat omhändertagande av patienter med gliom. Ett
vårdutvecklingsprojekt hos Cancerfonden 2000-2002, Slutrapport.
Bergenheim T, Malmström A, Bolander H, Michanek A, Stragliotto G, Damber L, Björ O, Henriksson R. Registrering av primära
hjärntumörer mått på nationell vårdkvalitet. Regionala skillnader avslöjade. Läkartidningen 2007; 104(5): 332-341.
Läs artikeln här!
Hardell LO, Carlberg M, Soderqvist F, Hansson Mild K, Morgan LL. Long-term use of cellular phones and brain tumours -
increased risk associated with use for > 10 years. Occup Environ Med. 2007 Apr 4; [Epub ahead of print].
Hardell L, Carlberg M, Hansson Mild K. Pooled analysis of two Swedish case-control studies on the use of mobile and
cordless telephones and the risk of brain tumours diagnosed during 1997-2003. Int J Occup Saf Ergon. 2007; 13(1): 63-71.
Hardell L, Hansson Mild K, Carlberg M, Soderqvist F. Tumour risk associated with use of cellular telephones or cordless
desktop telephones. World J Surg Oncol. 2006 Oct 11; 4: 74.
Hardell L, Carlberg M, Mild KH. Case-control study of the association between the use of cellular and cordless
telephones and malignant brain tumors diagnosed during 2000-2003. 2006 Feb; 100(2): 232-41. Epub 2005 Jul 14.
Ribom D, Schoenmaekers M, Engler H, Smits A. Evaluation of 11C-methionine PET as a surrogate endpoint after
treatment of grade 2 gliomas. J Neuro-oncol 2005; 71: 325-332.
Ribom D and Smits A. Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas.
Neurol Res 2005; 27: 516-21.
Ek L, Smits A, Påhlson A, Almqvist O. Analysis of cognitive dysfunction in patients with low-grade glioma. J Clin Psych
in Med 2005. Settings 12, 165-173.
Hardell L, Eriksson M, Carlberg M, Sundstrom C, Hansson Mild K. Use of cellular or cordless telephones and the risk for
non-Hodgkin's lymphoma. Int Arch Occup Environ Health. 2005 Sep; 78(8): 625-32. Epub 2005 Oct 12.
Hardell L, Carlberg M, Hansson Mild K. Case-control study on cellular and cordless telephones and the risk for acoustic
neuroma or meningioma in patients diagnosed 2000-2003. Neuroepidemiology. 2005; 25(3):120-8. Epub 2005 Jun 13.
Hardell L, Hansson Mild K, Carlberg M, Hallquist A. Cellular and cordless telephone use and the association with brain
tumors in different age groups. Arch Environ Health. 2004 Mar; 59(3): 132-7.
Ribom D, Smits A, Hartman M, Persson L, Blomquist E. On the issue of early and aggressive treatment in grade 2 gliomas.
J Cancer Res Clin Oncol 2003; 129: 154-160.
Ribom D, Westman-Brinkmalm A, Smits A, Davidsson P. Alpha-2-HS-glycoprotein in CSF of low-grade gliomas. Identification
by preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionisation-time of flight-mass
spectrometry. Tumor Biol 2003; 24: 94-99.
Ribom D, Larsson A, Pietras K, Smits A. Identification of growth factors (VEGF, PDGF and bFGF) in the CSF of patients
with low-grade gliomas. Neurol Sci 2003; 24: 70-73.
Påhlson A, Ek L, Ahlström G, Smits A. Pitfalls in the assessment of disability in individuals with low-grade gliomas.
J Neuro-oncol 2003; 65: 149-158.
Ribom D, Engler H, Blomquist E, Smits A. Potential significance of 11C-methionine PET as a marker for the
radiosensitivity of low-grade gliomas. Eur J Nucl Med 2002; 29: 632-640.
Ribom D, Andrae J, Friedlingsdorf M, Hartman M, Nistér M, Smits A. Prognostic value of PDGF alpha-receptor expression
in grade 2 astrocytomas and oligoastrocytomas grade 2. J Neurol Neurosurg Psych 2002; 72: 782-787.
Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B, Bolander H, Bergström M, Smits A. Positron Emission
Tomography 11C-methionine and survival in patients with low-grade gliomas. Cancer 2001; 92: 1541-1549.
Smits A, Ribom D. Risk of increased malignancy a reason for
follow-up of low grade glioma. Early identification of high-risk patients is the key to good care. Läkartidningen 2000; 97:
3886-3890.
Ribom D, Adner J, Eriksson A, Persson L, Smits A. Low-grade glioma in the Uppsala/Orebro region. Prognostic factors and
survival among 119 patients. Läkartidningen 2000; 97: 3880-3884. |
